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ABSTRACT:
Breast cancer brain metastases (BCBM) are detected with increasing incidence. 
In order to detect potential genes involved in BCBM, we first screened for genes 
down-regulated by methylation in cell lines with site-specific metastatic ability. The 
expression of five genes, CADM1, SPARC, RECK, TNFAIP3 and CXCL14, which were also 
found down-regulated in gene expression profiling analyses of BCBM tissue samples, 
was verified by qRT-PCR in a larger patient cohort. CADM1 was chosen for further 
down-stream analyses. A higher incidence of CADM1 methylation, correlating with 
lower expression levels, was found in BCBM as compared to primary BC. Loss of 
CADM1 protein expression was detected most commonly among BCBM samples as 
well as among primary tumors with subsequent brain relapse. The prognostic role of 
CADM1 expression was finally verified in four large independent breast cancer cohorts 
(n=2136). Loss of CADM1 protein expression was associated with disease stage, 
lymph node status, and tumor size in primary BC. Furthermore, all analyses revealed 
a significant association between loss of CADM1 and shorter survival. In multivariate 
analyses, survival was significantly shorter among patients with CADM1-negative 
tumors. Loss of CADM1 expression is an independent prognostic factor especially 
associated with the development of brain metastases in breast cancer patients.
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INTRODUCTION
Breast cancer (BC) is the most common non-skin 
malignancy in women affecting about 1.2 million women 
in the world each year. The spread of malignant cells from 
the primary tumor to distant organs such as the brain is 
the main cause of BC related deaths. Breast cancer is 
the second most common cause for the development 
of central nervous system (CNS) metastases, which 
are, irrespectively of the primary tumor origin, more 
commonly diagnosed than primary brain tumors [1, 2]. 
CNS-metastases are diagnosed in 15-20% of patients with 
metastatic BC and are usually occurring with a median 
time period of 31 months after the diagnosis of breast 
cancer [2]. Due to improved systemic treatment options 
for breast cancer, patients benefit from prolonged survival 
rates. However, consecutively to the longer survival and 
an intensified use of sensitive detection methods such as 
contrast-enhanced magnetic resonance imaging of the 
brain (cMRI), the incidence rates of brain metastases are 
rising. 
Brain metastases are often associated with the 
aggressive triple negative breast cancer (TNBC), being 
hormone receptor (HR) and HER2 negative, and also 
with HER2 positive primary breast cancers [3, 4]. Patients 
suffering from breast cancer brain metastases (BCBM) 
have an extremely poor prognosis with a median survival 
of only 7.8 months [3]. This brings forth to investigate 
new prognostic markers, which may be helpful for 
the identification of patients with an increased risk 
for subsequent CNS-infiltration and to develop new 
therapeutic approaches. 
The loss of tumor suppressor gene (TSG) expression 
is known to constitute a crucial step in cancer formation. 
For the dissemination and outgrowth of metastases, 
another set of metastasis suppressor and activator genes is 
needed. Metastasis suppressor genes (MSGs) usually do 
not influence tumor growth at the primary site, but control 
the tumor cells’ capacity to escape from the primary 
tumor and form overt metastases at distant sites [5]. 
MSGs contribute to dormancy control and/or outgrowth 
at secondary sites and thus regulate the final step of 
metastasis, the metastatic colonization. Interestingly, in 
contrast to TSGs, MSGs seem to be more often cancer 
type specific. Furthermore, MSGs are rarely mutated, and 
epigenetic events, such as methylation, are thus likely the 
main cause for their loss of function [6]. Since epigenetic 
events are reversible, dormancy control by MSGs is 
potentially a new form of targeted gene therapy (reviewed 
in [6, 7 ]).
The aim of this study was to identify novel genes 
involved in BCBM formation. We first screened for genes 
down-regulated by methylation in breast cancer cell lines 
(parental MDA-MB-231 cell line and the brain- and bone-
specific sub cell lines) known for site-specific metastasis 
[8]. Gene expression profiling and quantitative real-time 
RT-PCR (qRT-PCR) validation of the candidate genes 
were thereafter conducted on tumor tissues from primary 
BC and BCBM in order to identify the most clinically 
relevant genes. The methylation pattern of CADM1 
was furthermore characterized, and CADM1 protein 
expression was validated in two large independent primary 
tumor cohorts as well as in BCBM samples and correlated 
with clinico-pathological parameters.
RESULTS
Methylation array screening of brain metastases 
related genes
A subclone of MDA-MB-231 with a high metastatic 
potential to the brain, MDA-MB-231 BR, was compared to 
the parental MDA-MB-231 and to a bone-seeking variant 
MDA-MB-231 SA in order to identify genes, which might 
be specifically involved in brain metastasis formation. 
The cell lines were treated with 5-Aza-2’-deoxycytidine, 
a demethylating agent, in order to find genes potentially 
down-regulated by methylation. Microarray analysis was 
performed on pooled triplicate experiments and the non-
tumorigenic epithelial cell line MCF 10A was used to 
control for stress response after the treatment with 5-Aza-
2’-deoxycytidine.
The gene expression profiling after 5-Aza-2’-
deoxycytidine treatment revealed 914 different transcripts, 
which were significantly up-regulated in one of the MDA-
MB-231 cell lines but not altered in MCF 10A (Figure 
1A). The largest number of up-regulated genes (691 
transcripts) and cell line-specific up-regulated genes 
(20%) was found in the MDA-MB-231 BR cell line. Most 
of the genes were, however, up-regulated in all of these 
cell lines (30%, 279/914). In general, the more aggressive 
subclones BR and SA were more similar to each other than 
to the parental cell line, indicating a differentiation into 
generally more aggressive forms.
Gene expression screening for methylation-related 
genes in primary and metastatic breast tumors
Gene expression profiling of primary non-
metastasized breast tumors (n=32) and brain metastases 
(n=9) was performed to find the most relevant genes 
among the 690 potentially brain metastases determining 
genes detected in methylation array screening. 110 
transcripts (16%) of those up-regulated in the MDA-
MB-231 BR subclone in response to 5-Aza2’-
deoxycytidine treatment were found significantly lower 
expressed among the BCBM samples as compared to 
the samples from non-relapsed primary BC patients 
(Supplementary Table 2). 
Twenty-four (22%) of these genes were found 
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exclusively in the BR subclone, implicating a brain 
specific down-regulation of these genes. 28 genes were 
in common between the highly metastatic BR and SA 
variants, indicating that these genes may mediate a more 
aggressive behavior in general.
Validation of potential metastasis-suppressing 
genes in primary BC and BCBM tissue samples 
The expression of five genes, which we found 
down-regulated in the breast cancer data set and in the 
cell line analyses, was further investigated by qRT-PCR in 
39 primary BC samples without brain metastases and 20 
BCBM tissue samples. 
SPARC, RECK, TNFAIP3 and CXCL14 were down-
regulated (p < 0.05) in BCBM as compared to primary 
BC samples irrespectively of the cancer subtype, while 
for CADM1, this correlation was found in HR positive 
and TNBC samples (Figure 1B and Supplementary Figure 
1). Within the primary BC samples, 84% of the HER2 
negative patients showed an elevated CADM1 mRNA 
expression (top 75% percentile), whereas only 29% of the 
HER2 positive patients had a high CADM1 expression (p 
= 0.003) (Supplementary Figure 1). Among the primary 
tumors, high RECK expression was also associated with 
HR positive status, whereas the highest SPARC expression 
was statistically significantly linked to triple negative 
(TNBC) samples. CXCL14 expression was not associated 
with a subtype, but its low expression was associated with 
both positive lymph node status (p = 0.011) and high grade 
(p = 0.029) (Supplementary Table 3).
Frequency of CADM1 methylation in primary 
breast cancer and BCBM tissue samples
The methylation status of CADM1 was determined 
by MSP in 17 BCBM and 14 primary BC samples. 
CADM1 was homozygously methylated in 17.5% (3/17), 
Figure 1:A) Gene expression changes in response to 5-Aza-2’-deoxycytidine treatment in parental MDA-MB-231 breast cancer cell line 
and MDA-MB-231 BR and MDA-MB-231 SA variants. The number before brackets defines the genes up-regulated in each cell line after 
5-Aza-2’-deoxycytidine treatment. The number in brackets defines the number of genes also down-regulated in the brain metastases as 
compared to non-relapsed primary tumors. Figure 1B) Expression of CADM1, RECK, CXCL14, SPARC and TNFAIP3 in BCBM samples 
relative to primary breast tumors (PT). HR pos.: estrogen and progesterone positive receptor, TNBC: triple negative breast cancer. P- values 
were determined by the log rank test. 
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heterozygously methylated in 17.5% (3/17) and not 
methylated in 65% (11/17) of the BCBM samples. In 
contrast, primary BC samples showed no homozygous 
CADM1 methylation, only 7% (1/14) heterozygous and 
93% (13/14) WT CADM1 status (Figure 2). Due to the low 
frequency of methylation in the primary BC samples, no 
association between clinico-pathological factors and the 
methylation status of CADM1 could be found. 
CADM1 protein expression in primary and 
metastatic breast cancer  
CADM1 protein expression could be assessed in 
a large number of primary breast tumors (TMA I, n= 
1331) and 27 BCBM samples (Table 1, and Figure 3). 
Normal breast duct showed an intensive membranous 
staining for CADM1, whereas the tumor stroma was 
CADM1 negative. The CADM1 expression in the plasma 
membrane was lost in 42% of the primary BC and in 68% 
of the BCBM samples. Strong expression was recorded in 
22% of the primary BC and in 11% of the BCBM cases. 
The CADM1 protein expression differed between primary 
tumor and BCBM with more negative staining among the 
BCBM samples (p = 0.011).
Surprisingly, a nuclear staining of CADM1 was seen 
in a small subset of patients. Nuclear staining has been 
previously reported to occur in cervical epithelium with 
the localization of staining being dependent on epithelial 
origin [9]. 86 (6.5%) of the primary BC samples on the 
prognostic TMA (TMA I) had a clear CADM1 staining 
in the nucleus. The nuclear staining highly correlated 
with the membranous staining (p < 0.001). In 70 of the 
86 patients with nuclear staining, also the membrane was 
stained for CADM1 (81% concordance). 
In addition, 43 matched pairs of primary tumors and 
lymph node metastasis samples (TMA III) were analyzed 
for CADM1 protein expression. 70% (30/43) of the 
matched pairs showed a concordant CADM1 expression 
with 51% (22/43) of the primary tumor and lymph node 
samples being CADM1 negative and 19% (8/43) CADM1 
positive in both types of tissues. Only 7% (3/43) of the 
samples had a higher CADM1 expression in the lymph 
nodes as compared to the matched primary tumors, while 
down-regulation of CADM1 expression in the lymph node 
metastases was observed in 23% (10/43) of the matched 
pairs, indicating a loss of CADM1 protein expression 
during the metastatic cascade.
Comparison of gene expression, methylation 
pattern and protein expression status of CADM1 
in primary BC and BCBM
In order to find out how much of the silencing 
of expression is governed by promoter methylation, 
we compared the results from the qRT-PCR, IHC and 
methylation analyses. In 22 samples results from the gene 
expression, methylation and protein expression status for 
CADM1 were available (Table 2). 
Homozygous methylation was associated with a 
negative CADM1 staining and low or intermediate mRNA 
expression. Heterozygote methylation pattern showed a 
negative IHC result in 50% of the cases and for the rest 
Figure 2: Promoter CpG methylation of CADM1. A) 
Gel electrophoresis picture of CADM1 in 5 representative cases, 
MW= molecular weight marker, UM= unmethylated PCR, 
M= methylated PCR. B) Tables of MSP results for CADM1 of 
primary tumors and breast cancer brain metastases. WT= wild 
type, HET= heterozygous methylation, MET= homozygous 
methylation.
Figure 3: CADM1 immunostaining in primary breast 
cancer and BCBM samples. A) Primary BC sample 
with homogenous positive CADM1 membrane and negative 
nuclear staining, B) Primary BC sample with negative CADM1 
membrane and weak nuclear staining, C) BCBM sample with 
negative CADM1 membrane and nuclear staining with positively 
stained erythrocytes, D) BCBM sample with weak heterogeneous 
CADM1 membrane and negative nuclear staining.
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Table 1: CADM1 membrane protein expression in correlation to clinical parameters  in primary BC (TMA I) and BCBM.
CADM1 negative CADM1 weak CADM1 strong p-
valuen % n % n %
Brain metastases
All 19 67.9 6 21.4 3 10.7
Primary tumors
All 557 42.1 488 36.9 286 21.6
Histology n.s.
Ductal 408 42.1 361 37.2 201 20.7
Lobular 71 46.4 51 33.3 31 20.3
others  78 37.7 76 35.2 54 27.1
Tumor stage <0.001
pT1 118 27.6 185 43.0 125 29.0
pT2 290 44.8 224 34.6 133 20.6
pT3 40 52.6 25 32.9 11 14.5
pT4 106 60.6 52 29.7 17 9.7
n.a. 3 2 0
Lymph node status 0.003
pN0 193 35.8 219 40.6 127 23.6
pN1 207 44.6 159 34.3 98 21.1
pN2 43 53.8 28 35.0 9 11.3
n.a. 114 82 52
Grade n.s.
1 130 42.6 113 37.0 62 20.3
2 201 40.4 188 37.8 108 21.7
3 203 45.8 151 34.1 89 20.1
n.a. 23 36 27
Tumor size <0.001
< 2.0 cm 120 27.9 185 43.0 125 29.1
> 2.0 cm 421 48.4 290 33.3 159 18.3
n.a. 16 2.9 13 2.7 2 0.7
Hormone receptor n.s.
negative 126 44.3 87 32.8 65 22.9
positive 410 41.0 379 37.9 210 21.0
n.a. 21 22 11
HER2 n.s.
negative 438 40.4 403 37.2 242 22.3
positive 93 45.6 73 35.8 38 18.6
n.a. 26 12 6
Subtype 0.036
ER/PR pos. 350 40.4 332 38.3 185 21.3
TNBC 81 42.4 55 28.8 55 28.8
HER2 pos. 93 45.6 73 35.8 38 18.6
n.a. 33 28 8
Age 0.028
< 50 years 85 37.1 85 37.1 59 25.8
> 50 years 379 44.8 310 36.6 157 18.6
n.a. 93 93 70
Course of disease <0.001
dead 238 51.7 145 31.7 76 16.6
alive 319 36.6 343 39.3 210 24.0
n.a. = not available; n.s. = not significant
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a weak positive CADM1 protein staining was observed. 
Negative CADM1 protein expression was always 
associated with either low/ negative or intermediate 
mRNA expression. 
Clinical significance of CADM1 protein expression 
The clinical significance of CADM1 expression 
was assessed in two publicly available mRNA expression 
data sets (GSE3494 and GSE6532) and on two prognostic 
TMAs of primary BC samples (Figure 4). In both 
expression array data sets a significant association between 
low CADM1 expression and bad prognosis was found (p = 
0.033 and p = 0.001). 
The two prognostic TMAs (TMA I and TMA II) 
of primary BC gave highly consistent results. Clinico-
pathologic examination of both independent patient 
cohorts consisting of 1718 primary breast tumor samples 
revealed a significant association between negative 
CADM1 status and advanced tumor stage, positive lymph 
node status and larger tumor size (all p < 0.05; Table 1 
and Supplementary Table 4). In the TMA I a significant 
association between CADM1 and age, subtype and course 
of disease was also detected. The frequency distribution of 
CADM1 was comparable on the TMA II but significance 
was not reached due to smaller sample numbers. Grade 
Figure 4: Kaplan–Meier analysis of CADM1 mRNA and protein expression in primary breast cancer. A) Survival 
analyses in two publicly available expression data sets. B) Survival analyses for the prognostic TMA (TMA I) of the whole study population 
and among HR-positive patients. C) Survival analyses in the second TMA (TMA II) for the whole study population and among HR-positive 
patients. Survival differences were analyzed by the log rank test.
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was associated with CADM1 loss on the second TMA, 
whereas no difference between the different histological 
subtypes could be found on either TMA. 
The site of relapse was recorded for 353 primary 
tumor patients (TMA II). Among patients without relapse 
a loss of CADM1 was seen in 58.6%, whereas the highest 
frequency of CADM1 loss was seen among patients 
suffering from brain relapse with 81.1%. Also other 
types of relapse had a higher frequency of CADM1 loss 
compared to the non-relapsed (bone 73.8% (p = 0.023), 
liver 69.7% and lung 65.5%; Supplementary table 4). 
Consistent with the membranous staining, a 
statistically significant association between loss of 
CADM1 in the nucleus and more aggressive or advanced 
tumor stage and size, as well as for the hormone receptor 
status and the course of disease (p < 0.05) was found (only 
assessed on TMA I, Supplementary Table 5). In addition, 
the majority of cases with nuclear CADM1 staining was 
found among lobular tumors (11% vs. 6% in ductal, p = 
0.042).
A highly significant association between worse 
patient outcome (overall survival and disease free survival) 
and negative CADM1 protein expression could be found 
in both data sets (p < 0.001 and p = 0.006) (Figure 4). 
Loss of CADM1 was significantly associated with worse 
patient outcome among ductal carcinomas (p = 0.001 
and p = 0.001), whereas a significant association was 
found for lobular carcinomas only in TMA II (p = 0.026; 
TMA I p = 0.068) (data not shown). Furthermore, loss 
of CADM1 expression was significantly associated with 
shorter survival in HR positive (both data sets p = 0.001 
and p = 0.022, Figure 4), but did not have a prognostic 
relevance in HER2 positive patients, indicating a tumor 
suppressing effect of CADM1 in HER2 negative patients 
only (data not shown). Multivariate analysis showed that 
loss of CADM1 expression was a significant independent 
negative prognostic factor (TMA I p = 0.045 and TMA 
II p = 0.01). For the first larger study cohort (TMA I) the 
five-year survival was 64.8% (median 105 months) for 
patients with no CADM1 protein expression and 75.9% 
(154 months) and 77.7% for patients with weak and strong 
CADM1 expression respectively. For TMA II the five-year 
survival was 84.7% (median 179.7 months) for patients 
with no CADM1 protein expression and 92.3% (189 
months) and 95.2% (221 months) for patients with weak 
and strong CADM1 expression, respectively.
DISCUSSION
The incidence of brain metastases in breast cancer 
patients is increasing, with no standard diagnostic 
management of these patients applied in clinical routine. 
In view of the increasing success of targeted therapies in 
treating BC patients with distant metastases, improved 
insights into the phenotype of brain metastases could 
have important therapeutic implications. In the present 
study, we first screened for genes silenced by methylation 
in a breast cancer cell line with a high potential to form 
brain metastases. Five of the identified genes, also down-
regulated in clinical samples, CADM1, RECK, SPARC, 
CXCL14 and TNFAIP3, were chosen for further expression 
analyses. These genes have previously not been associated 
with brain metastasis formation. However, they have been 
implicated as cancer-relevant genes in epithelial tumors 
[10-14]. Furthermore, the methylation status of CADM1 
in primary BC and BCBM was investigated and CADM1 
protein expression was examined in correlation with 
clinico-pathological parameters in BC and compared 
to BCBM tissue samples. We identified CADM1 as 
an important prognostic factor, whose loss was not 
only associated with more aggressive primary BC with 
worse outcome, but also with an increased risk of brain 
metastasis formation. 
Table 2: Combined results from the qRT-PCR, 
MSP, and IHC analyses for CADM1
CADM1
Pat. No. Sample qPCR methylation IHC-result
BrM-9 BCBM INT MET NEG
BrM-10 BCBM LOW MET NEG
BrM-8 BCBM INT HET NEG
BrM-7 BCBM LOW HET NEG
BrM-5 BCBM LOW WT NEG
BrM-25 BCBM LOW WT NEG
BrM-19 BCBM LOW WT NEG
BrM-1 BCBM INT WT NEG
BrM-16 BCBM INT WT NEG
BrM-18 BCBM INT WT NEG
BrM-22 BCBM INT WT NEG
BrM-2 BCBM INT WT NEG
PT-95 PT INT WT NEG
PT-103 PT INT WT NEG
BrM-13 BCBM n.d. WT NEG
BrM-21 BCBM INT HET WEAK
PT-88 PT INT HET WEAK
BrM-15 BCBM INT n.d. WEAK
BrM-14 BCBM HIGH n.d. WEAK
BrM-24 BCBM LOW WT WEAK
PT-101 PT INT WT STRONG
BrM-11 BCBM HIGH WT STRONG
BCBM: breast cancer brain metastase; PT: primary tumor;
HIGH: CT expression value in upper quartile in all patients analyzed;
LOW: CT expression value in bottom quartile in all patients analyzed
n.d.: not defined; WT: wild type; HET: heterozygous methylation; 
MET: homozygous methylation; NEG: negative protein staining
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CADM1/TSLC1 (cell adhesion molecule 1) is 
a membrane-spanning glycoprotein belonging to the 
superfamily of immunoglobulin cell adhesion molecules. 
It was first recognized as a tumor suppressor in non-small 
cell lung cancer (NSCLC) [10]. It has been suggested 
that the disruption of cell adhesion through the loss of 
CADM1 is a mechanism leading to cancer cell invasion 
and metastasis [15, 16]. CADM1 is known to be 
involved in inhibition of cell proliferation and induction 
of apoptosis with a reported loss of expression in a 
variety of cancers of epithelial cell origin such as breast, 
prostate, pancreatic, hepatocellular and colorectal cancer, 
but also in neuroblastoma (reviewed in [16]). Recently, 
CADM1 was identified by Faraji et al. (2012) to be a 
metastasis susceptibility gene, i.e. an inherited factor 
that suppresses metastasis by sensitizing tumor cells to 
immunosurveillance by CD8+ T-cells [17]. 
We found a down-regulation of CADM1 both on 
mRNA and protein level in BCBM tissue samples as 
compared to primary BC. It was previously reported 
that CADM1 protein is detected on the cell membrane 
in normal epithelial cells of the breast and that negative 
CADM1 staining, detected in more than half of the 
primary BCs, is associated with advanced disease stages 
[18, 19]. Here, we found that in primary BC, loss of 
CADM1 was most commonly seen among TNBC and 
HER2 positive patients, two subtypes more closely 
associated with brain metastases. Furthermore, loss of 
CADM1 protein expression was associated with risk 
factors such as high tumor stage, positive lymph node 
status and large tumor size (all p < 0.05) in two large 
independent sample cohorts consisting of more than 
1 700 tumor samples, indicating a prognostic role for 
CADM1 in preventing breast cancer progression. Loss of 
CADM1 expression was found more commonly among 
primary tumor patients with lung, liver, bone or brain 
relapse compared to patients with no relapse. Importantly, 
loss of CADM1 expression was most commonly seen 
among patients with brain relapse indicating a special 
but not exclusive role of CADM1 in brain metastasis 
formation. Similarly, matched pairs of primary BC and 
lymph node (LN) metastasis samples were additionally 
analyzed for CADM1 protein expression, showing more 
frequently a down-regulation of CADM1 expression 
in the LN metastases. The observed down-regulation of 
CADM1 not only in BCBM but also in LN metastases 
as compared to the primary tumor supports the role of 
CADM1 as a metastasis susceptibility gene in terms of 
reducing the metastatic capability (25). This hypothesis 
is further supported by our results showing an association 
between CADM1 positive staining in primary tumors and 
longer overall survival. Multivariate analysis showed that 
CADM1 expression is an independent prognostic marker, 
strengthening the hypothesis that CADM1 may play an 
important role in preventing the metastatic progression. 
In line with the results from our expression studies, 
the CADM1 promoter region was found methylated 
in 35% of the BCBM samples, whereas in primary BC 
samples with good prognosis, CADM1 promoter was 
only methylated in 7% of the samples. However, other 
mechanisms resulting in a loss of gene function, such 
as deletion, need to be further investigated. Clearly, the 
predictive value for CADM1 in brain metastases formation 
needs to be tested on large matched samples sets in future 
studies.
In addition to CADM1, we also analyzed the 
expression of four other genes (RECK, SPARC, TNFAIP3 
and CXCL14) in primary BC and BCBM. All four 
genes were found down-regulated in BCBM patients as 
compared to primary BC. Further studies will be needed 
in order to assess their biological and clinical role in 
brain metastases formation. RECK protein is capable 
of inhibiting matrix metalloproteinases and plays an 
important role in embryogenesis and vasculogenesis 
[11]. RECK is often down-regulated in various primary 
epithelial cancers and gliomas, and the down-regulation 
correlates with poor prognosis (reviewed in [11, 20]). 
Recently, Hill et al (2011) showed that RECK down-
regulation by methylation in BC is associated with relapse 
and poor survival [21]. Furthermore, Hsu et al. showed 
that HER2 can repress RECK expression in order to 
promote cell invasion, which is consistent with our results 
showing the lowest expression of RECK among HER2 
positive patients [22].
SPARC/ osteonectin (secreted protein acidic and 
rich in cysteine) is a matricellular calcium-binding 
glycoprotein involved in cell adhesion, cell-matrix 
interactions during tissue remodelling, cell proliferation, 
migration, angiogenesis and apoptosis [12, 23]. Recently, 
Nagai et al. [24] described a correlation between reduced 
SPARC expression and advanced clinical stage and poor 
outcome in primary BC. SPARC expression in metastatic 
tissue has not been reported. Both CXCL14 (CXC motive 
ligand 14) and TNFAIP3/A20 (tumor necrosis factor 
α induced protein 3) are involved in immunoregulatory 
and inflammatory processes. CXCL14 is a pro-migratory 
chemokine and plays an important role in tumor 
recognition by the immune system [13]. TNFAIP3 is a 
zinc-finger protein involved in the cytokine-mediated 
immune and inflammatory response mainly through the 
inhibition of nuclear factor NF-κB (NFκB) activation and 
tumor necrosis factor (TNF)-mediated apoptosis [25]. 
Down-regulation of CXCL14 and TNFAIP3 has been 
described in various primary tumor entities including 
breast tumors [13, 14, 26, 27], but to our knowledge, their 
role in metastasis has not been reported.
In conclusion, our study shows a down-regulation of 
CADM1, RECK, SPARC, CXCL14 and TNFAIP3 in brain 
metastases samples and especially implies CADM1 as an 
important prognostic factor, which is commonly lost in BC 
subtypes with poor outcome and refers to an increased risk 
of brain metastasis formation. The mechanisms leading to 
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a loss of CADM1 expression are at least partially induced 
by promoter hypermethylation, a mechanism potentially 
reversible by therapeutic intervention. As loss of CADM1 
seems to represent in general a more aggressive disease 
with a higher risk of relapse especially to the brain, these 
patients might need a more frequent follow-up including 
diagnostics such as regular clinical controls and early 
cMRI of the brain. 
MATERIALS AND METHODS
Cell lines and patient material
For the methylation screening analysis, the human 
breast cancer cell line MDA-MB-231 (parental) and 
its bone- (SA) and brain-seeking (BR) variants were 
used. MDA-MB-231 was obtained from ATCC and 
passaged for a maximum of 6 months. MDA-MB-
231(SA) cells were obtained from Prof. Theresa Guise 
and were comprehensively characterized by comparative 
genomic hybridization and genome-wide gene expression 
profiling as described in Pollari et al. (2011) [28]. The 
brain metastatic MDA-MB-231 variant was obtained 
from Prof. Toshiyuki Yoneda and was characterized in 
[29]. A non-tumorigenic epithelial cell line MCF 10A 
(ATCC, USA) was used as a control (see supplementary 
material). Authentications of all cell lines were conducted 
by short tandem repeat (STR) profiling to exclude cross-
contamination between the cell lines.
For the qRT-PCR and methylation specific PCR 
(MSP) analyses, tumor tissue from 29 early stage primary 
BC patients and 21 BCBMs were collected from fresh 
frozen specimens (see supplementary material) [30]. 
Patient samples were obtained after surgical resection 
at the University Medical Center, Hamburg-Eppendorf 
(UKE), Germany. For the immunohistochemistry (IHC) 
analysis, three different sets of Tissue Micro Arrays 
(TMA) were used. The first large prognostic array (TMA 
I) consisted of 2197 primary breast cancer specimens 
operated in Basel, Switzerland [31]. Follow-up data were 
available for all patients with a median follow-up time 
of 61.0 months (range 7-171 months). The second TMA 
(TMA II) consisted of 243 invasive ductal carcinomas and 
243 invasive lobular carcinomas operated in Tampere, 
Finland, with a maximum follow-up period of 19.8 years 
containing information on the site and time of tumor 
recurrence and overall survival [32]. A third TMA from 
UKE (TMA III) contained 89 cases with matched primary 
and lymph node metastasis samples [33]. In addition, 
whole section slides from 28 BCBM patients were also 
analyzed by IHC (see supplementary material). The 
REMARK criteria were followed for the patient and study 
set up, however no information about the treatment could 
be collected. All sample donors from UKE gave written 
informed consent to biological research into their samples 
as approved by the ethics committee of the chamber of 
physicians, Hamburg, Germany. The use of the Finnish 
tumor samples and patient records was approved by the 
Ethics Committee of the Pirkanmaa Hospital District. All 
clinical investigations have been conducted according to 
the principles expressed in the Declaration of Helsinki.
5-Aza-2’-deoxycytidine treatment of cells and 
isolation of total RNA and DNA
Different concentrations of 5-Aza-2’-deoxycytidine 
were tested for minimal toxicity (MTT assay) but full 
reversion of methylation. The concentration of 1 µM has 
been found as the most efficient one. Cells were cultured 
in absence or presence of 1 µM 5-Aza-CdR (n=3), and 
the medium was changed daily until the cells reached 
a confluence of 90-100%. Experiments were done in 
triplicates using different cell passages (see supplementary 
material).
Tumor tissue sections were manually dissected to 
obtain a tumor cell content of at least 70% [34]. Total 
RNA was isolated with the RNeasy Mini Kit (Qiagen, 
Hilden, Germany). DNA was extracted using InnuPREP 
DNA Microkit (Analytik Jena, Jena, Germany) (see 
supplementary material). The success of 5-Aza-2’-
deoxycytidine treatment was verified by measuring the 
expression of methylated MAGE-A1 and RUNX3 genes 
[35, 36].
Genome-wide expression analysis
The gene expression analyses of the cell lines 
and BCBM samples were carried out using the Whole 
Human Genome Oligo Microarray Kit, 4x44K (Agilent 
Technologies) (see supplementary material). The non-
malignant cell line MCF 10A was used as a control for 
genotoxic stress response for the 5-Aza-2’-deoxycytidine 
treatment. The MIAME guidelines were followed in 
sample, array and data processing (see supplementary 
material). All array data are available at http://www.ncbi.
nlm.nih.gov/geo GSE44354.
Potentially methylated genes in BC cells were 
defined using the following criteria: a) 2-fold expression 
difference between the treated and non-treated MDA-
MB-231 BR cells, b) minimum expression value of 100 
in one of the cell lines, and c) no expression change in the 
control cell line MCF 10A after the 5-Aza-CdR treatment.
The array data from nine BCBM samples were 
compared to 32 untreated primary breast tumors without 
relapse present in the GEO DataSet GSE21974 [37]. 
Differentially expressed genes were selected using the 
significance analysis of microarrays (SAM) algorithm with 
a false discovery rate of 5%. Genes with expression values 
above 100, which were at least 2-fold down-regulated in 
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brain metastases as compared to primary tumors, were 
defined as potentially methylated. 
The prognostic impact of CADM1 expression was 
analyzed in two publicly available data sets (GSE3494 
and GSE6532) including follow-up data for 201 and 217 
patients respectively. The array data was median scaled 
whereas the CADM1 expression was divided in quartiles 
and the two middle quartiles were combined for the 
survival analyses. 
cDNA synthesis and qRT- PCR 
First Strand cDNA (Fermentas, St. Leon-Rot, 
Germany) was synthesized from 400 ng of total RNA. 
qRT-PCR reactions were run in duplicates and performed 
on the Mastercycler Eppendorf Realplex (Supplementary 
materials and Table 1). Data were analyzed by applying the 
∆∆CT-method using RPLP expression for normalization. 
The results, expressed as fold changes, were set in 
relation to Universal Human Reference expression (see 
supplementary material).
Methylation-specific PCR (MSP)
500 ng of genomic DNA were subjected to bisulfite 
treatment using the EZ DNA Methylation-Gold Kit 
(Zymo Research, Freiburg, Germany). DNA samples 
from bisulfite-treated MCF7 (positive) and HT29 
(negative) cells were utilized as controls in the CADM1 
MSP. According to the methylation pattern, the results 
were categorized into wild type (WT), heterozygously 
methylated and homozygously methylated (see 
supplementary material).
CADM1 IHC analysis
For CADM1 immunostaining, TMAs containing 
samples from primary tumors and lymph node metastases 
were employed. Additionally, 28 paraffin-embedded 
BCBM whole tissue sections were assessed. The rabbit 
polyclonal antibody anti-CADM1 (1:6000 dilution, 
S-4945, SIGMA-ALDRICH, Hamburg, Germany) 
was used and visualized using the DAKO ChemMate 
Detection Kit (#K 5001). The optimal dilution and pre-
treatment was defined by testing well characterized 
positive (MCF7 and MDA-MB468) and negative (MDA-
MB231, GI-101) formalin-fixed, paraffin-embedded 
(FFPE) cancer cell lines (for details see supplementary 
material). Normal tissue on the TMA with known negative 
(lymph nodes) and positive (normal epithelial cells of the 
colon and bronchus) protein expression of CADM1 served 
as positive and negative controls (see supplementary 
material).
Immunostaining was evaluated by two independent 
observers (HW and LW) and if discrepant findings 
were observed, the cases were reanalyzed together. The 
following parameters were taken into account: staining 
intensity (0-3), percentage of stained tumor cells (1-30% 
counted as 1, > 30-60% as 2, > 60-100% as 3) and the 
localization of staining in the tumor cells (membrane, 
nucleus). These scores were summed up to a total score, 
which was considered negative (score 0-1), weak (score 
2-4) or positive (score 5-6). 
Statistical analysis
Comparisons in distribution of clinical and 
pathological variables were examined using the Chi-
square-test (x²-test) or Fisher’s exact test. P-values 
lower than 0.05 were considered statistically significant. 
Cumulative survival probabilities were assessed from the 
date of initial diagnosis until death or the date of the last 
follow-up and analyzed using the Kaplan-Meier-method 
and two-tailed log-rank test. Multivariate analysis was 
performed using the Cox proportional hazards model by 
including histology, hormone receptor status, HER2 status, 
age, tumor-size, pT, pN, pM and grade as confounding 
factors. All statistical analyses were performed using the 
SPSS software version 21 (Chicago, IL, USA). 
ACKNOWLEDGEMENTS
We thank Prof. Toshiyuki Yoneda for providing 
the MDA-MB-231 BR cells and Prof. Theresa Guise for 
providing the MDA-MB-231(SA) cells as well as Kathrin 
Eylmann, Ina Hohensee and Regina Peters for excellent 
technical assistance. The work was founded by ERC 
Advanced Investigator Grant (DISSECT, ERC-2010-
AsG_20100317, KP). 
REFERENCES
1. Lin NU, Bellon JR and Winer EP. CNS metastases in breast 
cancer. J Clin Oncol. 2004; 22(17):3608-3617.
2. Tabouret E, Chinot O, Metellus P, Tallet A, Viens P 
and Goncalves A. Recent trends in epidemiology of 
brain metastases: an overview. Anticancer Res. 2012; 
32(11):4655-4662.
3. Arslan UY, Oksuzoglu B, Aksoy S, Harputluoglu H, Turker 
I, Ozisik Y, Dizdar O, Altundag K, Alkis N and Zengin 
N. Breast cancer subtypes and outcomes of central nervous 
system metastases. Breast. 2011; 20(6):562-567.
4. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders 
C, Ewend M and Perou CM. Genomic analysis identifies 
unique signatures predictive of brain, lung, and liver 
relapse. Breast Cancer Res Treat. 2011; 132(2):523-535.
5. Shoushtari AN, Szmulewitz RZ and Rinker-Schaeffer CW. 
Metastasis-suppressor genes in clinical practice: lost in 
Oncotarget3086www.impactjournals.com/oncotarget
translation? Nat Rev Clin Oncol. 2011; 8(6):333-342.
6. Horak CE, Lee JH, Marshall JC, Shreeve SM and Steeg 
PS. The role of metastasis suppressor genes in metastatic 
dormancy. APMIS. 2008; 116(7-8):586-601.
7. Hurst DR and Welch DR. Metastasis suppressor genes 
at the interface between the environment and tumor cell 
growth. Int Rev Cell Mol Biol. 2011; 286:107-180.
8. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen 
DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens 
JA and Massague J. Genes that mediate breast cancer 
metastasis to the brain. Nature. 2009; 459(7249):1005-
1009.
9. Overmeer RM, Henken FE, Snijders PJ, Claassen-Kramer 
D, Berkhof J, Helmerhorst TJ, Heideman DA, Wilting 
SM, Murakami Y, Ito A, Meijer CJ and Steenbergen RD. 
Association between dense CADM1 promoter methylation 
and reduced protein expression in high-grade CIN and 
cervical SCC. J Pathol. 2008; 215(4):388-397.
10. Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, 
Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka 
M, Kitamura T, Sekiya T, Reeves RH and Murakami Y. 
TSLC1 is a tumor-suppressor gene in human non-small-cell 
lung cancer. Nat Genet. 2001; 27(4):427-430.
11. Clark JC, Thomas DM, Choong PF and Dass CR. RECK-
-a newly discovered inhibitor of metastasis with prognostic 
significance in multiple forms of cancer. Cancer Metastasis 
Rev. 2007; 26(3-4):675-683.
12. Arnold SA and Brekken RA. SPARC: a matricellular 
regulator of tumorigenesis. J Cell Commun Signal. 2009; 
3(3-4):255-273.
13. Gu XL, Ou ZL, Lin FJ, Yang XL, Luo JM, Shen ZZ and 
Shao ZM. Expression of CXCL14 and its anticancer role in 
breast cancer. Breast Cancer Res Treat. 2012; 135(3):725-
735.
14. Ungerback J, Belenki D, Jawad Ul-Hassan A, Fredrikson 
M, Fransen K, Elander N, Verma D and Soderkvist P. 
Genetic variation and alterations of genes involved in 
NFkappaB/TNFAIP3- and NLRP3-inflammasome signaling 
affect susceptibility and outcome of colorectal cancer. 
Carcinogenesis. 2012; 33(11):2126-2134.
15. Nakahata S and Morishita K. CADM1/TSLC1 is a novel 
cell surface marker for adult T-cell leukemia/lymphoma. J 
Clin Exp Hematop. 2012; 52(1):17-22.
16. Liang QL, Chen GQ, Li ZY and Wang BR. Function and 
histopathology of a cell adhesion molecule TSLC1 in 
cancer. Cancer Invest. 2011; 29(2):107-112.
17. Faraji F, Pang Y, Walker RC, Nieves Borges R, Yang L 
and Hunter KW. Cadm1 is a metastasis susceptibility gene 
that suppresses metastasis by modifying tumor interaction 
with the cell-mediated immunity. PLoS Genet. 2012; 
8(9):e1002926.
18. Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, Sakurai-
Yageta M, Ito A, Goto A, Saito M, Kasumi F and Murakami 
Y. Aberrant expression of tumor suppressors CADM1 and 
4.1B in invasive lesions of primary breast cancer. Breast 
Cancer. 2011; 19(3):242-252.
19. Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, 
Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer 
W, Depisch D, Pirker R, Zielinski CC and Zochbauer-
Muller S. Downregulation of TSLC1 and DAL-1 expression 
occurs frequently in breast cancer. Breast Cancer Res Treat. 
2007; 103(3):283-291.
20. Silveira Correa TC, Massaro RR, Brohem CA, Taboga 
SR, Lamers ML, Santos MF and Maria-Engler SS. RECK-
mediated inhibition of glioma migration and invasion. J Cell 
Biochem. 2010; 110(1):52-61.
21. Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis 
C, Maher ER and Latif F. Genome-wide DNA methylation 
profiling of CpG islands in breast cancer identifies novel 
genes associated with tumorigenicity. Cancer Res. 2011; 
71(8):2988-2999.
22. Hsu MC, Chang HC and Hung WC. HER-2/neu represses 
the metastasis suppressor RECK via ERK and Sp 
transcription factors to promote cell invasion. J Biol Chem. 
2006; 281(8):4718-4725.
23. Brekken RA and Sage EH. SPARC, a matricellular protein: 
at the crossroads of cell-matrix communication. Matrix 
Biol. 2001; 19(8):816-827.
24. Nagai MA, Gerhard R, Fregnani JH, Nonogaki S, Rierger 
RB, Netto MM and Soares FA. Prognostic value of NDRG1 
and SPARC protein expression in breast cancer patients. 
Breast Cancer Res Treat. 2011; 126(1):1-14.
25. Hymowitz SG and Wertz IE. A20: from ubiquitin editing to 
tumour suppression. Nat Rev Cancer. 2010; 10(5):332-341.
26. Song EY, Shurin MR, Tourkova IL, Gutkin DW and Shurin 
GV. Epigenetic mechanisms of promigratory chemokine 
CXCL14 regulation in human prostate cancer cells. Cancer 
Res. 2010; 70(11):4394-4401.
27. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura 
S, Morishima Y and Seto M. TNFAIP3/A20 functions as 
a novel tumor suppressor gene in several subtypes of non-
Hodgkin lymphomas. Blood. 2009; 114(12):2467-2475.
28. Pollari S, Kakonen SM, Edgren H, Wolf M, Kohonen P, 
Sara H, Guise T, Nees M and Kallioniemi O. Enhanced 
serine production by bone metastatic breast cancer cells 
stimulates osteoclastogenesis. Breast Cancer Res Treat. 
2011; 125(2):421-430.
29. Yoneda T, Williams PJ, Hiraga T, Niewolna M and 
Nishimura R. A bone-seeking clone exhibits different 
biological properties from the MDA-MB-231 parental 
human breast cancer cells and a brain-seeking clone in 
vivo and in vitro. Journal of bone and mineral research : 
the official journal of the American Society for Bone and 
Mineral Research. 2001; 16(8):1486-1495.
30. Wikman H, Sielaff-Frimpong B, Kropidlowski J, Witzel 
I, Milde-Langosch K, Sauter G, Westphal M, Lamszus 
K and Pantel K. Clinical relevance of loss of 11p15 in 
primary and metastatic breast cancer: association with loss 
Oncotarget3087www.impactjournals.com/oncotarget
of PRKCDBP expression in brain metastases. PLoS One. 
2012; 7(10):e47537.
31. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, 
Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, 
Kallioniemi OP and Sauter G. Tissue microarrays for rapid 
linking of molecular changes to clinical endpoints. Am J 
Pathol. 2001; 159(6):2249-2256.
32. Alarmo EL, Huhtala H, Korhonen T, Pylkkanen L, Holli 
K, Kuukasjarvi T, Parkkila S and Kallioniemi A. Bone 
morphogenetic protein 4 expression in multiple normal and 
tumor tissues reveals its importance beyond development. 
Mod Pathol. 2013; 26(1):10-21.
33. Hein S, Muller V, Kohler N, Wikman H, Krenkel S, 
Streichert T, Schweizer M, Riethdorf S, Assmann V, 
Ihnen M, Beck K, Issa R, Janicke F, Pantel K and Milde-
Langosch K. Biologic role of activated leukocyte cell 
adhesion molecule overexpression in breast cancer cell lines 
and clinical tumor tissue. Breast Cancer Res Treat. 2011; 
129(2):347-360.
34. Wrage M, Ruosaari S, Eijk PP, Kaifi JT, Hollmen J, 
Yekebas EF, Izbicki JR, Brakenhoff RH, Streichert T, 
Riethdorf S, Glatzel M, Ylstra B, Pantel K and Wikman 
H. Genomic profiles associated with early micrometastasis 
in lung cancer: relevance of 4q deletion. Clin Cancer Res. 
2009; 15(5):1566-1574.
35. Wischnewski F, Pantel K and Schwarzenbach H. Promoter 
demethylation and histone acetylation mediate gene 
expression of MAGE-A1, -A2, -A3, and -A12 in human 
cancer cells. Mol Cancer Res. 2006; 4(5):339-349.
36. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, 
Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, 
Ito Y and Sukumar S. RUNX3 is frequently inactivated by 
dual mechanisms of protein mislocalization and promoter 
hypermethylation in breast cancer. Cancer Res. 2006; 
66(13):6512-6520.
37. Wikman H, Lamszus K, Detels N, Uslar L, Wrage M, 
Benner C, Hohensee I, Ylstra B, Eylmann K, Zapatka M, 
Sauter G, Kemming D, Glatzel M, Muller V, Westphal M 
and Pantel K. Relevance of PTEN loss in brain metastasis 
formation in breast cancer patients. Breast Cancer Res. 
2012; 14(2):R49.
